A detailed history of Raymond James & Associates transactions in Cor Medix Inc. stock. As of the latest transaction made, Raymond James & Associates holds 47,837 shares of CRMD stock, worth $494,156. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,837
Previous 49,832 4.0%
Holding current value
$494,156
Previous $215,000 79.53%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$3.64 - $8.23 $7,261 - $16,418
-1,995 Reduced 4.0%
47,837 $386,000
Q2 2024

Jul 19, 2024

BUY
$4.08 - $6.39 $16,340 - $25,591
4,005 Added 8.74%
49,832 $215,000
Q1 2024

Apr 22, 2024

BUY
$2.94 - $4.24 $8,820 - $12,720
3,000 Added 7.0%
45,827 $194,000
Q4 2023

Jan 16, 2024

BUY
$3.0 - $4.01 $17,400 - $23,258
5,800 Added 15.66%
42,827 $161,000
Q3 2023

Oct 24, 2023

BUY
$3.6 - $4.46 $720 - $892
200 Added 0.54%
37,027 $136,000
Q2 2023

Jul 25, 2023

BUY
$3.94 - $5.8 $7,880 - $11,600
2,000 Added 5.74%
36,827 $145,000
Q1 2023

Apr 14, 2023

BUY
$3.22 - $4.61 $3,864 - $5,532
1,200 Added 3.57%
34,827 $144,000
Q1 2022

May 11, 2022

SELL
$3.83 - $6.24 $9,954 - $16,217
-2,599 Reduced 7.17%
33,627 $184,000
Q4 2021

Feb 08, 2022

BUY
$4.47 - $5.56 $17,053 - $21,211
3,815 Added 11.77%
36,226 $165,000
Q3 2021

Nov 02, 2021

BUY
$4.46 - $7.11 $49,671 - $79,184
11,137 Added 52.35%
32,411 $151,000
Q2 2021

Aug 11, 2021

SELL
$6.05 - $10.09 $17,091 - $28,504
-2,825 Reduced 11.72%
21,274 $146,000
Q1 2021

May 14, 2021

BUY
$6.84 - $17.58 $12,989 - $33,384
1,899 Added 8.55%
24,099 $241,000
Q3 2020

Nov 04, 2020

BUY
$3.96 - $6.15 $47,864 - $74,335
12,087 Added 119.52%
22,200 $134,000
Q2 2020

Jul 28, 2020

SELL
$3.08 - $6.56 $1,047 - $2,230
-340 Reduced 3.25%
10,113 $64,000
Q1 2020

Apr 21, 2020

BUY
$2.35 - $7.08 $24,564 - $74,007
10,453 New
10,453 $38,000

Others Institutions Holding CRMD

About CorMedix Inc.


  • Ticker CRMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,208,200
  • Market Cap $426M
  • Description
  • CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...
More about CRMD
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.